Maybe the Pandemic Will Never End
(Bloomberg Opinion) -- So far, the response to the coronavirus pandemic has operated on the assumption that the worst will be over within a year or so. But what if the malaise lasts much longer? It's a scenario that policy makers must recognize and prepare for.
Breathless media constantly repeat that a vaccine might be widely available by next spring. But even spring of 2023 would be the fastest in medical history, and there's no guarantee of that. Maybe antibodies will turn out to confer little or no protection from infection, as is true for some viruses. In that case, developing a vaccine would be a lot harder, and the concept of “herd immunity” would be meaningless. Almost everyone would remain susceptible, whether or not they'd had it in the past.
So a very long battle with Covid-19 seems entirely possible – while it seems nearly impossible that the U.S. and much of the world can follow New Zealand's lead and almost eliminate the disease. A longer-term crisis would have very different implications for the economy. Sectors that are expected to bounce back – such as tourism – could be out for good. Sectors that have seen a boost – such as streaming services – could be permanent winners.
Yet all the emergency relief from governments and central banks is aimed at easing only a temporary shock. In the U.S., the Federal Reserve, the Treasury and Congress have worked assiduously (and successfully) to ensure that companies have roughly equal access to funding. This would be defensible if officials were sure that the pandemic will pass within a year. But they can't be. If we're in this for the long haul, their actions are encouraging overinvestment in economic activities that face truly existential risks.
The same is true for certain social-distancing measures. The Centers for Disease Control, for example, recommends that long-term care facilities refuse all visitations “except for certain compassionate care reasons, such as end-of-life situations.” Some have suggested that all elderly people remain isolated. This might be bearable for a year. But it seems cruel and unenforceable over longer time frames. We need to be asking: How can a society provide safe and compassionate care for the elderly and vulnerable if Covid-19 remains widespread for many years?
This disease has the potential to impose enormous and lasting change upon the world. Scientists are doing all they can to prevent such an outcome, by defeating the virus quickly. But economic and public-health policy makers should be planning for the possibility that they won't succeed.
This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Narayana Kocherlakota is a Bloomberg Opinion columnist. He is a professor of economics at the University of Rochester and was president of the Federal Reserve Bank of Minneapolis from 2009 to 2015.
©2020 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.